- Home
- PDEX vs HURA Comparison
PDEX vs HURA Comparison
Compare PDEX & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDEX
- HURA
- Stock Information
- Founded
- PDEX 1978
- HURA 2009
- Country
- PDEX United States
- HURA United States
- Employees
- PDEX N/A
- HURA N/A
- Industry
- PDEX Medical/Dental Instruments
- HURA
- Sector
- PDEX Health Care
- HURA
- Exchange
- PDEX Nasdaq
- HURA Nasdaq
- Market Cap
- PDEX 152.3M
- HURA 145.6M
- IPO Year
- PDEX N/A
- HURA N/A
- Fundamental
- Price
- PDEX $36.39
- HURA $2.35
- Analyst Decision
- PDEX Strong Buy
- HURA Strong Buy
- Analyst Count
- PDEX 1
- HURA 2
- Target Price
- PDEX $56.00
- HURA $11.50
- AVG Volume (30 Days)
- PDEX 35.5K
- HURA 512.4K
- Earning Date
- PDEX 10-30-2025
- HURA 08-14-2025
- Dividend Yield
- PDEX N/A
- HURA N/A
- EPS Growth
- PDEX 345.00
- HURA N/A
- EPS
- PDEX 2.67
- HURA N/A
- Revenue
- PDEX $66,593,000.00
- HURA N/A
- Revenue This Year
- PDEX $7.22
- HURA N/A
- Revenue Next Year
- PDEX N/A
- HURA N/A
- P/E Ratio
- PDEX $13.58
- HURA N/A
- Revenue Growth
- PDEX 23.68
- HURA N/A
- 52 Week Low
- PDEX $23.45
- HURA $1.80
- 52 Week High
- PDEX $70.26
- HURA $8.40
- Technical
- Relative Strength Index (RSI)
- PDEX 33.31
- HURA 38.39
- Support Level
- PDEX $35.05
- HURA $2.43
- Resistance Level
- PDEX $47.81
- HURA $2.65
- Average True Range (ATR)
- PDEX 2.36
- HURA 0.18
- MACD
- PDEX -1.03
- HURA -0.07
- Stochastic Oscillator
- PDEX 10.00
- HURA 6.86
About PDEX Pro-Dex Inc.
Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.